25 February 2021BiotechAlex Baldwin

Five minutes with… Irena Royzman

Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

10x Genomics dealt major blow in sequencing fight

20 August 2026 Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.

Biotech

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

17 August 2026 Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.

Biotech

Masimo keeps $634m smartwatch award and moves to appeal

21 July 2026 Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.

More features

10x Genomics dealt major blow in sequencing fight

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

Abbott fends off Chinese rival’s patent challenge at UPC

Former head of litigation at Nokia returns to Bird & Bird

Former USPTO acting director takes the helm at C4IP

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

Novartis scores UK win in high-stakes Entresto fight

Five minutes with… Irena Royzman

More on this story

Editor's picks

Editor's picks

More features